PFAS health risks: new studies sharpen the picture

Two recent peer reviewed publications add further weight to the growing body of evidence linking PFAS exposure to adverse human health outcomes. While neither fundamentally changes the direction of travel, both reinforce an important point for businesses: scientific understanding of PFAS risks continues to evolve in ways that support increasingly precautionary regulatory approaches.

The first study, published in PLOS Medicine, examines the relationship between prenatal PFAS exposure and childhood respiratory health. Based on a cohort of more than 11,000 children in Sweden, the authors used drinking water contamination data to estimate exposure levels and linked these to health outcomes recorded over more than a decade.

The key finding is that very high prenatal PFAS exposure was associated with a significantly increased incidence of childhood asthma, with hazard ratios indicating a materially higher risk compared to background exposure populations. This association was not observed at lower exposure levels, which is an important nuance, but the signal at the higher end is clear.

Importantly, the study focuses on a population exposed via contaminated drinking water, reflecting real world exposure scenarios associated with firefighting foams and historical industrial uses. This reinforces a wider evidence base suggesting that early life exposure to PFAS can affect developing organ systems, including the immune and respiratory systems.

The second publication, a 2026 narrative review in F&S Reviews, takes a broader look at PFAS exposure across the reproductive life course, from preconception through pregnancy and early life. It brings together recent epidemiological and mechanistic studies to assess impacts on female fertility and pregnancy outcomes.

The review concludes that PFAS are consistently detected in reproductive tissues and can cross key physiological barriers, including the placenta. Across multiple studies, exposure is associated with impaired ovarian function, altered reproductive hormones, and reduced success rates in assisted reproductive technologies.

The evidence also extends into pregnancy outcomes. The review highlights associations between PFAS exposure and hypertensive disorders of pregnancy, fetal growth restriction, and preterm birth, alongside mechanistic insights pointing to placental dysfunction, oxidative stress, and mitochondrial disruption as potential underlying pathways.

Taken together, these studies illustrate a consistent pattern emerging across different endpoints and stages of life. PFAS are not linked to a single health effect but to a broad and still expanding set of potential impacts, particularly where exposure occurs during sensitive developmental windows. This aligns with the wider literature pointing to endocrine disruption, developmental effects and long term health outcomes.

From a regulatory and compliance perspective, the direction of travel is clear. As the evidence base grows, regulators are increasingly likely to take a precautionary, group based approach to PFAS management, rather than continuing with substance by substance assessments. This is already evident in proposed restrictions under EU REACH and ongoing work in the UK.

For businesses, the implication is not simply a future compliance challenge but a current need to understand exposure pathways within their own products and supply chains. As these studies underline, risk is not purely theoretical and may relate to real world exposure scenarios with tangible health outcomes.

The practical takeaway is straightforward. Organisations should be asking where PFAS may be present, how they are used, and whether those uses remain defensible in the face of evolving science and regulation. As with previous developments in chemicals regulation, those who act early are likely to be better placed than those who wait for formal restrictions to crystallise.